Nomax SRL
Nomax reported total assets of €1.85m at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Apr 2026).
The score of Nomax shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +101 % Total assets +132 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Nomax's annual accounts
Filed annual accounts
- Year ended 30 Sep 2025filed on 30 Apr 2026
- Year ended 30 Sep 2024filed on 30 Apr 2025
- Year ended 30 Sep 2023filed on 29 Apr 2024
- Year ended 30 Sep 2022filed on 27 Apr 2023
- Year ended 30 Sep 2021filed on 28 Apr 2022
Nomax's financial analysis
- Solvency72.7%sector median: 46.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Nomax
Nomax's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0535.727.337
- VAT number
- BE0535727337
- Peppol
- Registered · 0208:0535727337 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 14 Jun 2013
- Registered office
- 3690 Zutendaal
- Latest accounts
- 2025 · filed on 30 Apr 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Nomax (SRL) has been based in Zutendaal since 2013, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 585,181 € and equity of €1.35m; its revenue is not published. Its solvency stands at 72.7%, above the median of its sector (46.0%).
Companies similar to Nomax
Companies in the same business, of comparable size and area, outside its group.
- Medline International Belgium Manufacture of medical and dental instruments and supplies Machelen (Brab.) · balance sheet €15.0m
- Cerdak Manufacture of pharmaceutical preparations Lanaken · balance sheet 103,436 €
- Gentaur Molecular Products Wholesale of pharmaceutical and medical goods Kampenhout · balance sheet €1.24m
- BIO-RAD Laboratories Wholesale of pharmaceutical and medical goods Lokeren · balance sheet €8.58m
- Hyloris Wholesale of pharmaceutical and medical goods Liège · balance sheet €1.58m
- Cirba Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 67,062 €
- Medical Services Boom Wholesale of pharmaceutical and medical goods Boom · balance sheet €1.64m
- Protex Healthcare Wholesale of pharmaceutical and medical goods Roeselare · balance sheet €2.77m
Frequently asked questions about Nomax
What is the revenue of Nomax?
Nomax files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Nomax?
In Belgium, the VAT number is the company number prefixed with BE: BE0535727337 for Nomax, if the company is VAT-registered. Its company number (CBE) is 0535.727.337.
Where is the registered office of Nomax?
According to the CBE register, the registered office of Nomax is in 3690 Zutendaal.
What is the equity of Nomax?
At the close of the 2025 financial year, the equity of Nomax amounts to 1,347,723 €, a solvency of 72.7% of total assets.
Who manages Nomax?
The register lists 1 active mandates at Nomax. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Nomax
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →